Immediate consultation is warranted if you develop: Rapid weight gain accompanied by swelling, shortness of breath, or decreased urine output (possible fluid retention or heart failure) Return of obesity-related complications such as uncontrolled blood pressure, worsening diabetes control (elevated blood glucose readings), or sleep apnea symptoms Severe increase in appetite that interferes with daily functioning or leads to binge eating episodes Psychological distress, depression, or anxiety related to weight changes Severe abdominal pain, especially radiating to the back, with or without vomiting (possible pancreatitis) Right upper quadrant abdominal pain, fever, or yellowing of skin/eyes (possible gallbladder disease) Gastrointestinal symptoms that persist after stopping Zepbound Follow-up schedule should be tailored to your individual risk factors and comorbidities
PGC1A regulates the IRS1:IRS2 ratio during fasting to influence hepatic metabolism downstream of insulin
You can use 2 films consecutively or with intervals
Hold in mouth for 20 seconds before swallowing
It also reduced enteric serotonin release while suppressing intestinal motility
These included changes in body weight, waist circumference, waist to height ratio (WHtR), BMI category, and cardiometabolic risk factors such as blood pressure, cholesterol, blood fats, glucose measures and hs-CRP
